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Does Carotid Intima-Media Thickness Regression
Predict Reduction of Cardiovascular Events?
A Meta-Analysis of 41 Randomized Trials
Pierluigi Costanzo, MD, Pasquale Perrone-Filardi, MD, PHD, Enrico Vassallo, MD,
Stefania Paolillo, MD, Paolo Cesarano, MD, Gregorio Brevetti, MD, Massimo Chiariello, MD
Naples, Italy
Objectives The purpose of this study was to verify whether intima-media thickness (IMT) regression is associated with re-
duced incidence of cardiovascular events.
Background Carotid IMT increase is associated with a raised risk of coronary heart disease (CHD) and cerebrovascular (CBV)
events. However, it is undetermined whether favorable changes of IMT reflect prognostic benefits.
Methods The MEDLINE database and the Cochrane Database were searched for articles published until August 2009. All
randomized trials assessing carotid IMT at baseline, at end of follow-up, and reporting clinical end points were
included. A weighted random-effects meta-regression analysis was performed to test the relationship between
mean and maximum IMT changes and outcomes. The influence of baseline patients’ characteristics, cardiovas-
cular risk profile, IMT at baseline, follow-up, and quality of the trials was also explored. Overall estimates of ef-
fect were calculated with a fixed-effects model, random-effects model, or Peto method.
Results Forty-one trials enrolling 18,307 participants were included. Despite significant reduction in CHD, CBV events,
and all-cause death induced by active treatments (for CHD events, odds ratio [OR]: 0.82, 95% confidence inter-
val [CI]: 0.69 to 0.96, p  0.02; for CBV events, OR: 0.71, 95% CI: 0.51 to 1.00, p  0.05; and for all-cause
death, OR: 0.71, 95% CI: 0.53 to 0.96, p  0.03), there was no significant relationship between IMT regression
and CHD events (tau 0.91, p  0.37), CBV events (tau 0.32, p  0.75), and all-cause death (tau 0.41,
p  0.69). In addition, subjects’ baseline characteristics, cardiovascular risk profile, IMT at baseline, follow-up,
and quality of the trials did not significantly influence the association between IMT changes and clinical out-
comes.
Conclusions Regression or slowed progression of carotid IMT, induced by cardiovascular drug therapies, do not reflect reduc-
tion in cardiovascular events. (J Am Coll Cardiol 2010;56:2006–20) © 2010 by the American College of Cardi-
ology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.05.059
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varotid intima-media thickness (IMT) increase predicts the
isk of cardiovascular events (1), with relatively stronger
rognostic power for cerebral as compared with coronary
ascular events (2). In fact, increased IMT is considered to
epresent a manifestation of subclinical atherosclerosis, and,
herefore, it has been included in the list of organ damage
onditions in the European hypertension guidelines (3) and
n the European prevention guidelines (4). The lack of
nvasiveness and repeatability makes IMT measurement an
ttractive biomarker, potentially useful as a therapeutic
arget in subjects at increased cardiovascular risk (5). There-
rom the Department of Internal Medicine, Cardiovascular Sciences, and Immunol-
gy, Federico II University, Naples, Italy. The authors have reported that they have
o relationships to disclose. The first 2 authors contributed equally to this work. Profs.
revetti and Chiariello are deceased.c
Manuscript received February 12, 2010; revised manuscript received April 23,
010, accepted May 17, 2010.ore, IMT changes (either regression or slowed progression)
ave been employed as surrogate clinical end points in
everal randomized clinical studies using lipid-lowering
Online Appendix references 1–21), antihypertensive (On-
ine Appendix references 6,22–28), oral antidiabetic (Online
ppendix references 23,29–31), and antioxidant drugs
Online Appendix references 32–35) in subjects at interme-
iate to high cardiovascular risk.
However, although clinical events were generally reported
n these trials, none of them was designed to verify whether
hanges in IMT are associated with consistent changes in
he cardiovascular subjects’ risk profile (6). Yet, this infor-
ation would be relevant for the interpretation of IMT
ariations as surrogate clinical end points and use as thera-
eutic targets for monitoring and optimization of cardio-
ascular therapies in several categories of subjects at in-
reased cardiovascular risk (5,7).
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December 7, 2010:2006–20 Carotid IMT Changes and Cardiovascular EventsTherefore, the aim of the present study was to assess,
sing a meta-regression analysis of all available randomized
rials, whether reduced progression or regression of IMT is
ssociated with reduced incidence of major cardiovascular
vents in subjects at intermediate to high cardiovascular risk.
ethods
earch strategy and data extraction. This study was de-
igned according to the QUOROM (Quality of Reporting
eta-analyses) statement (8). Inclusion criteria for a study
o be included were as follows: evaluation of carotid IMT at
aseline and at end of follow-up; report of major clinical
ardiovascular end points (coronary heart disease events
CHD] including acute coronary syndrome, CHD death,
evascularization, angina pectoris; cerebrovascular [CBV]
vents, including transient ischemic attack and stroke, or
ll-cause death); comparison of active drug treatments or of
n active drug versus placebo, or of different doses of active
rugs; and randomized protocol design. Observational stud-
es without longitudinal follow-up and cross-sectional stud-
es were excluded.
The MEDLINE database, the Cochrane database, and the
SI Web of Science were searched for articles published in
nglish and other languages until August 2009. Studies were
dentified through PubMed searches of the MEDLINE da-
abase with the following headings: IMT, carotid atherosclero-
is, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-COA) re-
uctase inhibitor, statin, lipid lowering, fibrate, nicotinic
cid, a:cholesterol acyltransferase (ACAT) inhibitor,
holesteryl-ester transfer protein (CETP) inhibitor, diet,
ife-style, antihypertensive, angiotensin-converting enzyme
ACE) inhibitor, calcium-channel blocker, angiotensin-
Figure 1 Meta-Analysis Flow Chart
Flow chart showing the progress through the stages of the meta-analysis.eceptor blocker, antidiabetic
gent, insulin, diuretic, beta-
locker, alpha-antagonist, ran-
omly, random, randomized
ontrolled trials, atherosclerosis.
e searched reference lists of the
etrieved articles to identify other
ligible studies, and information
rom colleagues was used to
dentify more recently published
rticles.
Two reviewers independently
elected potentially eligible trials
ccording to fulfillment of inclusion criteria. Selected trials
ere compared, and any discrepancies were resolved by
iscussion and consensus. Two reviewers independently
ead the full text of retained studies and included trials that
et the inclusion criteria. Articles finally selected for the
eview were checked to avoid inclusion of data published in
uplicate. Data on baseline characteristics, presence of diabetes
ellitus, hypertension, smoking, carotid IMT measure-
ent at baseline and end follow-up, lipid serum level,
utcomes as all-cause mortality and CHD and CBV
vents were abstracted. We also calculated for each trial a
omposite outcome including CHD and CBV events; a
ardiovascular hard event outcome including acute coro-
ary syndrome, cardiac death, and stroke; and a cardio-
ascular soft event outcome including stable angina,
oronary revascularization, heart failure hospitalization,
nd transient ischemic attack. When a potentially eligible
rial was retrieved, but the paper lacked essential infor-
ation to be included in the analysis (i.e., number of
Abbreviations
and Acronyms
CBV  cerebrovascular
CHD  coronary heart
disease
CI  confidence interval
IMT  intima-media
thickness
LDL  low-density
lipoprotein
OR  odds ratio
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Carotid IMT Changes and Cardiovascular Events December 7, 2010:2006–20vents, detailed information about IMT), the authors
ere contacted to request further information (Fig. 1).
Both mean and maximum IMT values were consid-
red. Mean IMT was defined as the mean of all mea-
urements on common carotid artery or, when this value
as not available, a single measurement on common
arotid artery. Maximum IMT was defined as the mean
aseline Characteristics of Trials Included in OverviewTable 1 Baseline Characteristics of Trials Included in Overview
Trial Name/
First Author Year
Treatment
Category Treatment
ACAPS 1994 Lipid lowering Lovastatin
Angerer et al. 2001 Antioxidants Fish oil/PUFA
ARBITER 2002 Lipid lowering Atorvastatin
ARBITER 2 2004 Lipid lowering Niacinstatin
ASAP 2001 Lipid lowering Atorvastatin
ASFAST 2006 Antioxidants Folic acid/vitamin B12
ATIC 2007 Lipid lowering Pravastatin
BCAPS statin only 2001 Lipid lowering Fluvastatin
BCAPS statin
beta-blocker
2001 Anti-HTN Metoprolol
Beishuizien et al. 2004 Lipid lowering Cerivastatin
BVAIT 2009 Antioxidants Folic acid/vitamin B12
CAIUS 1996 Lipid lowering Pravastatin
CAPTIVATE 2009 Lipid lowering Pactimibestatin
DAPHNE 2002 Anti-HTN Doxazosin
ELSA 2002 Anti-HTN Lacidipine
ENHANCE 2008 Lipid lowering Simvastatinezetimibe
EPAT 2001 Other Estradiol
FAST 2002 Lipid lowering Pravastatin
FIELD 2008 Lipid lowering Fenofibrate
Hodis et al. 2006 Oral antidiabetics Troglitazone
HYRIM 2004 Lipid lowering Fluvastatin
KAPS 1995 Lipid lowering Pravastatin
Mazzone et al. 2006 Oral antidiabetics Pioglitazone
METEOR 2007 Lipid lowering Rosuvastatin
MIDAS 1996 Anti-HTN Isradipine
MITEC 2009 Anti-HTN Candesartan
Mitsuhashi et al. 2004 Other Cilostazol
PHYLLIS 2004 Lipid lowering Pravastatin
PLAC II 1995 Lipid lowering Pravastatin
PREVEND IT 2005 Lipid lowering Pravastatin
RADIANCE 1 2007 Lipid lowering Torcetrapibatorvastatin
RADIANCE 2 2007 Lipid lowering Torcetrapibatorvastatin
RAS 2007 Oral antidiabetics Rosiglitazone
REGRESS 1998 Lipid lowering Pravastatin
RIS 1996 Lipid lowering Life-style
SANDS 2008 Lipid lowering Standard statin
treatment
Shinoda-Tagawa et al. 2002 Other Cilostazol
Stanton et al. 2001 Anti-HTN Amlodipine
STARR ACE inhibitor 2009 Anti-HTN Ramipril
STARR glitazone 2009 Oral antidiabetics Rosiglitazone
VEAPS 2002 Antioxidants Vitamin E
VHAS 1998 Anti-HTN Verapamil
Yu et al. 2007 Lipid lowering Atorvastatin
ee Online Appendix for references and description of study acronyms.
ACE  angiotensin-converting enzyme; BMI  body mass index; CHD  coronary heart disease;f all maximum measurements, or when this value was tot available, the measurement at bulb or the single
aximum value.
The quality of the trials was evaluated giving a score for
ach study using the Detsky method (9) (Table 1).
Of 9,722 articles identified by the initial search, 85 were
etrieved for more detailed evaluation, and 41 were included
n the study (Fig. 1). Details of included trials and popula-
Control
Population
Intervention Age (yrs) Treatment (n) Control (n)
ebo Primary 62 460 459
ebo Secondary 58 87 84
astatin Secondary 60 79 82
in Secondary 67 87 80
vastatin Secondary 48 160 165
ebo Secondary 56 156 159
ebo Secondary 53 47 46
ebo Primary 62 395 398
ebo Primary 62 396 397
ebo Primary 59 125 125
ebo Primary 61 254 252
ebo Primary 55 151 154
in Secondary 55 443 438
Secondary 59 41 39
olol Primary 56 755 764
vastatin Primary 46 357 363
ebo Primary 61 97 102
ebo Primary 66 83 163
ebo Secondary 62 87 83
ebo Primary 53 142 134
ebo Primary 57 142 143
ebo Primary 57 224 223
epiride Secondary 59 230 228
ebo Primary 57 702 282
Primary 58 442 441
odipine Primary 60 100 109
ebo Primary 63 31 31
ebo Primary 58 254 254
ebo Secondary 75 76
ebo Primary 51 317 325
vastatin Primary 46 450 454
vastatin Primary 57 377 375
ebo Primary 68 277 278
ebo Secondary 56 131 124
al care Secondary 66 81 83
ressive
tatin  ezetimibe)
Primary 56 223 204
ebo Secondary 60 43 46
opril Secondary 49 35 34
ebo Primary 54 715 710
ebo Primary 54 709 716
ebo Primary 56 162 170
rthalidone Secondary 54 244 254
vastatin Secondary 66 57 55
hydroclorothiazide; HTN  hypertension; NR  not reported; PUFA  polyunsaturated fatty acids.Plac
Plac
Prav
Stat
Sim
Plac
Plac
Plac
Plac
Plac
Plac
Plac
Stat
HCT
Aten
Sim
Plac
Plac
Plac
Plac
Plac
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Glim
Plac
HCT
Aml
Plac
Plac
Plac
Plac
Ator
Ator
Plac
Plac
Usu
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Plac
Plac
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December 7, 2010:2006–20 Carotid IMT Changes and Cardiovascular Eventstatins or other lipid-lowering drugs treatments versus
lacebo or active treatments (Online Appendix references
–21), 8 trials compared antihypertensive drugs versus active
reatment or placebo (Online Appendix references 6,23–8),
trials compared oral antidiabetic agents versus active
reatment or placebo (Online Appendix references 22,29–
ontinuedTable 1 Continued
Women (%) BMI (kg/m2) Follow-Up (yrs) Smokers (%) Hypertens
48 26 3 12 29
18 NR 2 15 48
29 NR 1 10 69
9 NR 1 10 75
61 26 2 32 NR
51 26 3.6 10 90
43 27 2 35 31
54 26 3 31 12
54 26 3 31 12
40 31 2 24 50
39 30 3 3 NR
47 25 3 24 NR
39 28 1.25 16 29
0 26 3 46 100
45 27 3.75 20 100
51 27 2 28 16
100 29 2 0 0
73 23 2 53 41
37 29 5 14 56
67 32 2 NR 67
NR 29 4 15 100
0 NR 3 26 33
63 32 1.3 NR 70
40 27 2 22 28
22 28 3 20 100
63 31 3 NR 100
35 24 1 NR 60
60 NR 3 16 100
NR NR 3 NR NR
37 NR 2 39 24
49 27 2 20 24
64 30 2 16 50
51 30 1 13 57
0 26 2 32 26
0 27 3.4 35 100
67 34 3 19 NR
49 23 3.2 NR 57
40 NR 1 27 100
55 30 3 11 41
55 30 3 11 40
NR NR 3 36 0
48 27 4 18 100
17 NR 1 43 511), and 4 trials compared antioxidant agents versus placebo cOnline Appendix references 32,35). Additionally, 1 trial
ompared an a:cholesterol acyltransferase inhibitor versus
lacebo (Online Appendix reference 36), 1 trial compared
strogens versus placebo (Online Appendix reference 37), 2
rials compared phosphodiesterase inhibitors versus placebo
Online Appendix references 38,39), and 2 trials compared
) Diabetes (%) CHD (%)
Detsky
Quality Score
Event Rate Year
% Treatment % Control
2 0 19 0.4 0.7
0 53 19 1.1 3.6
10 46 18 3.8 3.7
27 43 21 3.4 8.8
NR 31 21 0.6 0.6
23 21 20 9 8.8
0 0 20 2.1 6.5
3 4 17 0.6 0.9
3 4 17 0.4 1.1
100 0 19 0 1.6
NR NR 18 1.2 1.5
NR 0 18 0.7 0.4
5 65 21 4.5 2.4
0 39 19 3.3 1.7
NR NR 18 0.9 1.1
2 28 21 1.4 1.1
3 0 19 1.5 2
23 14 18 3 4
100 20 20 0.5 1.2
100 0 18 2.1 2.2
NR 0 17 1.1 1.6
2 8 19 1.3 2.5
100 18 20 2 6.1
0 0 21 0.4 0.2
0 4 20 3.3 1.8
100 NR 21 0.7 0.6
100 0 16 0 6.5
NR 0 18 0.3 0.5
NR 100 18 1.8 4.4
4 3 20 1.4 2.3
3 0 21 0.4 0.1
21 0 21 0.4 0
36 7 21 1.1 0.7
NR 100 18 5.3 10.1
NR 17 2.2 2.1
100 0 17 1.5 1.1
100 NR 17 0 1.4
0 0 19 2.9 2.9
0 0 20 0.7 1.1
0 0 20 1.1 0.7
0 0 20 2.1 2.7
NR NR 18 1 1.9
28 100 19 10.5 7.3ion (%holesteryl-ester transfer protein inhibitors versus placebo
IMT ValuesTable 2 IMT Values
Trial Name/
First Author
Mean IMT Max IMT Change Mean IMT Change Max IMT
Mean
IMT
(%)
Max
IMT
(%)
Total
Cholesterol,
Mean
(mg/dl)
LDL,
Mean
(mg/dl)
HDL,
Mean
(mg/dl)
Triglycerides,
Mean
(mg/dl)
LDL
(%)
Treatment
(mm)
Control
(mm)
Treatment
(mm)
Control
(mm)
Treatment
(mm/yr)
Control
(mm/yr)
Treatment
(mm/yr)
Control
(mm/yr)
ACAPS 1.14 1.14 1.32 1.315 NR NR 0.0060 0.0060 NA 2.7 235 155 52 318 28
Angerer et al. 1.26 1.31 1.54 1.65 0.035 0.025 0.0300 0.0150 1.6 1.9 NR 155 50 193 4
ARBITER 0.625 0.615 0.935 0.808 0.034 0.025 0.1370 0.0020 9.5 15.9 229 152 49 207 18
ARBITER 2 0.893 0.868 NR NR 0.014 0.044 NR NR 3.4 NA 154 89 40 163 3
ASAP 0.86 0.87 1.09 1.07 0.0155 0.018 0.0110 0.0310 7.7 7.8 386 315 46 165 7
ASFAST 0.86 0.86 1.06 1.08 NR NR 0.0067 0.0100 NA 9.0 197 126 42 186 NA
ATIC 0.68 0.65 NR NR 0.025 0.03 NR NR 16.5 NA 224 138 48 164 31
BCAPS statin only 0.8945 0.909 1.9315 1.9055 0.0037 0.012 0.0567 0.0703 2.8 2.1 237 160 54 103 23
BCAPS statinbeta-
blocker
0.9115 0.892 1.9225 1.884 0.0073 0.008 0.0513 0.0757 0.2 3.8 240 163 54 103 NA
Beishuizien et al. 0.759 0.757 0.823 0.815 0.0015 0.003 0.0085 0.0050 0.4 0.9 212 135 47 164 31
BVAIT 0.075 0.076 NR NR 0.002 0.0003 NR NR 6.8 NA 217 134 57 130 NA
CAIUS 0.89 0.85 1.06 1.04 0.0032 0.0077 0.0430 0.0089 3.8 14.8 259 182 54 138 20
CAPTIVATE 0.785 0.775 0.937 0.927 0.0152 0.004 0.0136 0.0104 1.8 0.4 219 140 52 136 6
DAPHNE 1.05 1.08 1.39 1.43 0.005 0.0267 0.0500 0.0600 6.1 2.1 240 151 38 178 3
ELSA 1.1589 1.1619 1.3115 1.3131 0.0101 0.0125 NR NR 0.8 NA 227 145 53 136 1
ENHANCE 0.69 0.7 0.8 0.8 0.0056 0.0029 0.0088 0.0052 0.8 0.9 400 319 47 159 16
EPAT 0.766 0.764 NR NR 0.0019 0.0016 NR NR 0.1 NA 253 166 55 160 6
FAST 1.267 1.316 1.267 1.316 0.088 0.025 0.0880 0.0250 17.5 17.5 251 164 56 152 13
FIELD 1.03 1.01 1.3 1.29 0.004 0.004 0.0100 0.0080 0.0 0.8 190 119 44 142 23
Hodis et al. 0.809 0.821 NR NR 0.003 0.0066 NR NR 0.9 NA 197 176 50 115 NA
HYRIM 0.793 0.804 1.496 1.628 0.012 0.0185 0.0350 0.0535 3.3 4.7 225 148 50 157 NA
KAPS 1.66 1.66 2 2 0.0097 0.0283 0.0280 0.0400 3.4 1.8 259 189 46 150 31
Mazzone et al. 0.771 0.779 1.038 1.042 0.0008 0.0092 0.0015 0.0200 1.7 2.3 NR 113 48 175 4
METEOR 0.76 0.76 1.15 1.17 0.0004 0.0088 0.0014 0.0130 2.2 2.5 229 155 50 130 49
MIDAS 1.17 1.17 1.45 1.44 0.0403 0.0497 0.0513 0.0693 2.4 3.7 217 147 48 327 NA
MITEC 0.758 0.726 NR NR 0.0053 0.013 NR NR 3.1 NA 178 107 44 147 0
Mitsuhashi et al. 1.08 1.08 NR NR 0.04 0.12 NR NR 7.4 NA 191 104 52 155 3
PHYLLIS 1.065 1.06 1.205 1.22 NR NR 0.0231 0.0133 NA 7.8 266 183 54 142 20
PLAC II NR NR NR NR 0.0593 0.0675 0.0900 0.1040 NA NA 235 166 41 171 30
PREVEND IT NR NR NR NR NR NR NR NR 0.5 NA NR NR NR NR NR
RADIANCE 1 0.71 0.72 1.13 1.15 0.005 0.005 0.0050 0.0050 2.8 0.0 213 139 53 97 13
RADIANCE 2 0.83 0.83 1.32 1.3 0.0065 0.004 0.0125 0.0150 0.6 0.4 186 101 48 167 9
RAS 1.46 1.43 1.95 1.92 0.049 0.06 0.0880 0.1010 0.8 0.7 213 135 52 116 7
REGRESS 0.87 0.86 1.08 1.07 0.025 0.0000 0.0250 0.0050 5.8 5.6 239 168 38 163 29
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eta-regression analysis. Weighted random-effects
eta-regression analysis was performed with the metareg
ommand (10) (STATA version 10.0, StataCorps, College
tation, Texas) to test the relationship between changes in
MT from baseline to end of follow-up and incidence of
linical events. For this analysis, the achieved differences
etween IMT change (millimeters per year) in the control
roup and the active treatment group both for mean and
aximum IMT (delta mean IMT and delta maximum
MT, respectively) were considered. To explore the influ-
nce of potential effect modifiers on the association between
MT changes and outcomes, separate meta-regression anal-
ses were performed also, including the following covariates,
ach separately: mean age, sex, body mass index, smokers,
iabetes, hypertension, total serum cholesterol at baseline,
ow-density lipoprotein (LDL) at baseline and achieved
ifference between groups (from baseline to end of follow-
p), systolic and diastolic blood pressure at baseline and
chieved difference between groups (from baseline to end of
ollow-up), IMT mean and maximum at baseline, length of
ollow-up, Detsky quality score (9), and study publication
ear. Meta-regression analysis was also performed to test the
ssociation between LDL cholesterol reduction and the
utcomes.
For all meta-regression analyses, a random-effects model
as used to take into account the mean of a distribution of
ffects across studies. In fact, random-effects modeling more
ppropriately provides wider confidence intervals (CIs) for
he regression coefficients than does a fixed-effect analysis, if
esidual heterogeneity exists (11). The weight used for each
rial was the inverse of the sum of the within-trial variance
nd the residual between trial variance, in order to corre-
pond to a random-effects analysis. To estimate the additive
between-study) component of variance, tau, the re-
tricted maximum likelihood (REML) method was used to
ake into account the occurrence of residual heterogeneity,
ot explained by the potential effect modifiers (11).
Finally, to investigate a potential relationship between
ean and maximum IMT modification and LDL serum
evel change, we performed a linear regression analysis
eighted by the size of each study.
utcome meta-analysis. Odds ratios (ORs) of the effect of
andomized treatments were calculated using the metan rou-
ine (STATA version 10.0, StataCorps) (12). The OR and CI
or each outcome was separately calculated for each trial, with
rouped data, in intention-to-treat analyses. The choice to use
R was driven by the retrospective design of the meta-analysis
n the basis of published studies that vary in design, subjects’
opulation, treatment regimen, primary outcome measure, and
uality (12–14). Overall estimates of effect were calculated with
fixed-effects model, random-effects model, or Peto method
here appropriate. The assumption of homogeneity between
he treatment effects in different trials was tested with the Q
2and the I-square statistic. If the assumption of homogeneityCo T R
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Carotid IMT Changes and Cardiovascular Events December 7, 2010:2006–20as rejected (p  0.10), additional analyses were done with a
andom-effects model and sensitivity analysis (15). Further-
ore, in case events rate were 1%, analysis was also per-
ormed with the Peto method (16). Pooled ORs were loga-
ithmically transformed and weighted for the inverse of
aseline and End Follow-Up Blood PressureTable 3 Baseline and End Follow-Up Blood Pressure
Trial Name/
First Author
Treatment Group Control Group
Baseline
SBP
(mm Hg)
Baseline
DBP
(mm Hg)
Baseline
SBP
(mm Hg)
Baselin
DBP
(mm Hg
ACAPS 130 76 131 77
Angerer et al. NR NR NR NR
ARBITER NR NR NR NR
ARBITER 2 NR NR NR NR
ASAP 127 77 128 77
ASFAST 144 83 141 79
ATIC 136 79 134 78
BCAPS statin only 140 85 139 84
BCAPS statinbeta-blocker 138 85 139 85
Beishuizien et al. NA NA NA NA
BVAIT 128 80 129 80
CAIUS 133 81 134 81
CAPTIVATE 128 128 78 78
DAPHNE 163 100 164 101
ELSA 164 101 163 101
ENHANCE 125 78 124 78
EPAT 128 129 78 77
FAST NR NR NR NR
FIELD 142 88 140 88
Hodis et al. 137 80 134 79
HYRIM 140 88 140 88
KAPS 136 86 137 86
Mazzone et al. 130 78 129 77
METEOR 124 77 125 78
MIDAS 151 97 149 96
MITEC 156 91 156 92
Mitsuhashi et al. 135 71 130 72
PHYLLIS 160 98 160 98
PLAC II NR NR NR NR
PREVEND IT 130 76 130 76
RADIANCE 1 116 73 116 73
RADIANCE 2 121 75 120 75
REGRESS 134 80 137 82
RAS 141 83 142 83
RIS 145 80 151 83
SANDS 127 73 131 75
Shinoda-Tagawa et al. 138 80 134 77
Stanton et al. 165 99 164 101
STARR ACE inhibitor 134 81 135 82
STARR glitazone 135 82 135 82
TRIPOD 113 70 115 71
VEAPS 128 77 128 76
VHAS 168 102 168 102
Yu et al. NR NR NR NR
elta systolic blood pressure (SBP) and diastolic blood pressure (DBP) correspond to the achieved
or references and description of study acronyms.
Abbreviations as in Tables 1 and 2.ariance. The significance level for the overall estimates of vffect and for meta-regression analyses was set at p  0.05.
articipants could only contribute with 1 event to the calcula-
ion of each outcome, but could contribute with 1 event for
ach of the separate analyses of different outcomes.
ensitivity analysis. Sensitivity analysis was performed to
Treatment Group Control Group
SBP
(%)
DBP
(%)
Change in
SBP
(mm Hg)
Change in
DBP
(mm Hg)
Change in
SBP
(mm Hg)
Change in
DBP
(mm Hg)
NA NA NA NA NA NA
NA NA NA NA NA NA
NA NA NA NA NA NA
NA NA NA NA NA NA
NA NA NA NA NA NA
NA NA NA NA NA NA
2 1 0 2 1.5 3.8
4 0 3 0 0.7 0.0
2 0 3 0 0.7 0.0
NA NA NA NA NA NA
NA NA NA NA NA NA
NA NA NA NA NA NA
NA NA NA NA NA NA
NA NA NA NA NA NA
22 15 22 16 0.0 1.0
NA NA NA NA NA NA
NA NA NA NA NA NA
NA NA NA NA NA NA
6 8 2 8 2.8 0.0
NA NA NA NA NA NA
1 NA 1 NA 1.4 0.0
NA NA NA NA NA NA
NA NA NA NA NA NA
NA NA NA NA NA NA
16 13 19 13 2.0 0.0
25 14 25 16 0.0 2.2
5 2 5 1 0.0 1.4
18 13 17 13 0.6 0.0
NA NA NA NA NA NA
NA NA NA NA NA NA
4 2 1 2 2.6 0.0
7 2 1 1 5.0 1.3
NA NA NA NA NA NA
1 2 3 0 2 2
5 1 4 4 0.7 6.1
11 7 2 2 7.0 6.8
3 4 0 0 2.2 5.1
21 14 20 15 0.6 1.0
8 5 3 3 3.7 2.5
7 5 5 4 1.5 1.2
4 4 3 3 0.9 1.4
NA NA NA NA NA NA
25 15 28 16 1.8 1.0
NA NA NA NA NA NA
en-group difference from baseline to end of follow-up, expressed in percent. See Online Appendixe
)
betweerify the robustness of the results. In detail, to assess the
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December 7, 2010:2006–20 Carotid IMT Changes and Cardiovascular Eventsnfluence of the baseline profile risk, separate meta-
egression analysis and meta-analysis were performed for
rimary and secondary prevention trials. To evaluate the
pecific effect of treatment category, meta-regression anal-
sis and meta-analysis were performed separately for treat-
ent category (lipid lowering, antihypertensive, antidia-
etic, antioxidant therapy). To assess the influence of mean
nd maximum IMT baseline value, we used them as
ovariates in meta-regression analysis (see Results, Meta-
egression analysis), and we also made a meta-regression
nalysis including only trials with a mean or maximum IMT
1 mm (17). Furthermore, progression and regression of
ean and maximum IMT were also assessed separately.
hen, the influence of several potential effect modifiers on
he association between IMT changes and outcomes was
lso explored (see Results, Meta-regression analysis). Fi-
ally, as previously stated, IMT measurements were ex-
ressed in millimeters per year; however, we also performed
he meta-regression analysis by using the achieved differ-
nces between IMT percent change in the control group
nd the active treatment group both for mean and maxi-
um IMT.
Figure 2 Meta-Regression Analysis Between Delta Mean and M
Meta-regression analysis between delta mean and maximum (max) intima-media th
cular (CBV) events. The log of odds ratios (ORs) is reported on the y-axis, and the
inverse of the variance.To explore nonlinearity in the associations between each
utcome and delta mean and maximum IMT (18), the
plined models (19) were used. This analysis allows a cubic
ssociation in each of several subintervals of continuous
actor’s range, but requiring linearity at the beginning
nd end of the range and requiring that the pieces join
moothly (19).
ublication bias. To evaluate potential publication bias, a
eighted linear regression was used, with the natural log of
he OR as the dependent variable and the inverse of the
otal sample size as the independent variable. This is a
odified Macaskill’s test, which gives more balanced type I
rror rates in the tail probability areas in comparison with
ther publication bias tests (20).
esults
haracteristics of included trials. The baseline charac-
eristics of the 41 trials (18,307 participants) included in
he meta-analysis are shown in Tables 1, 2, and 3; 9,313
ubjects were assigned to a statin and 8,994 to another
rug or to placebo. The duration of follow-up ranged
rom 0.5 to 5 years, and the mean was 2.4  0.96 years.
um IMT, CHD, and CBV Events
ss (IMT) for (A, B) coronary heart disease (CHD) events and (C, D) cerebrovas-
ate is reported on the x-axis. Bubble size for each study is proportional to theaxim
ickne
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Carotid IMT Changes and Cardiovascular Events December 7, 2010:2006–20he overall mean age of subjects was 58  5 years, and
3% were women.
eta-regression analysis. When all data from the 41 trials
ere pooled, there was no significant relationship between
elta mean and delta maximum IMT changes from baseline
o end of follow-up and CHD, CBV events, composite
utcome, and all-cause death (Figs. 2 and 3, Tables 4 and 5).
ikewise, no relationship was found when only hard car-
iovascular events (cardiac death, myocardial infarction,
nd stroke) were considered (Online Appendix Fig. 1 and
able 1).
In addition, lack of relationship was confirmed when
re-specified potential effect modifiers (listed in Methods)
ere considered in the meta-regression analysis (Table 6).
In contrast, meta-regression analysis of lipid-lowering
rials demonstrated a significant relationship between LDL
owering and reduction of CHD events (Online Appendix
ig. 2) and composite outcome (Online Appendix Fig. 3),
ith a trend for CBV events (Online Appendix Fig. 2), and
o statistically significant association for all-cause death
Online Appendix Fig. 3).
However, no significant relationship between change in
ean or maximum IMT and LDL serum modification was
Figure 3 Meta-Regression Analysis Between Delta Mean and M
Meta-regression analysis between delta mean and maximum (max) intima-media th
Log of odds ratios (OR) is reported on the y-axis, and the covariate is reported onound (Online Appendix Figs. 4 and 5). For further details
bout these statistical analysis, refer to the legends of the
espective figures.
ensitivity analysis. Sensitivity analysis was performed to
eparately assess the association between IMT changes and
utcomes for primary (n  23) and secondary (n  18)
revention trials, for lipid lowering (n  21), antihypertensive
n 8), antidiabetic (n 4), and antioxidant therapy (n 4).
imilar to the overall pooled analysis, no significant relation-
hip between IMT changes and outcomes was observed in any
f these separate analysis (Tables 4 and 5). Analyzing the
nfluence of covariates listed in Methods, the only notable
esult was that in primary prevention, change in systolic blood
ressure significantly influenced the association between max-
mum IMT changes and CHD risk modification (Exp(b)1.33,
tandard error 0.12, 95% CI: 1.08 to 1.65, change in tau 
.19, p  0.015).
We also performed a meta-regression analysis considering
eparately progression and regression of carotid mean and
aximum IMT, and also in this case, no significant association
etween change in IMT and outcomes was observed (Online
ppendix Table 2). The influence of mean and maximum
aseline IMT value was considered, including them as covari-
um IMT, Composite Outcome, and All-Cause Death
ss (IMT) for (A, B) composite outcome and (C, D) all-cause death.
xis. Bubble size for each study is proportional to the inverse of the variance.
2axim
ickne
the x-a
a
a
i
p
s
b
t
c
O
a
a
p
A
C

C
0
f
0
n
s
c
f
D
C
0
i
e
h
t
P
a
D
T
E9
T lue is *
2015JACC Vol. 56, No. 24, 2010 Costanzo et al.
December 7, 2010:2006–20 Carotid IMT Changes and Cardiovascular Events
2te in the analysis (Table 6), and performing a meta-regression
nalysis in trials with mean or maximum IMT1 mm. Again,
n both cases no significant association was found.
The analysis was also performed by using the IMT
ercent change from baseline; however, the results did not
ignificantly differ (data not shown).
Exploring a potential nonlinearity in the associations
etween the outcomes and delta mean and maximum IMT
hrough the splined models (19) did not show any signifi-
ant nonlinear relationship for all outcomes.
utcomes analysis. Pooling all trials included in the meta-
nalysis, the risk of all-cause death was significantly reduced by
ctive treatments (OR: 0.71, 95% CI: 0.53 to 0.96, comparison
 0.03, heterogeneity p  0.91) (Online Appendix Fig. 6).
trend for risk reduction by active treatments was observed for
HD events (OR: 0.87, 95% CI: 0.74 to 1.03, comparison p
0.09, heterogeneity p 0.03) (Online Appendix Fig. 7), for
BV events (OR: 0.90, 95% CI: 0.77 to 1.05, comparison p
.08, heterogeneity p  0.09) (Online Appendix Fig. 8), and
xp(b) of Delta Mean Intima-Media Thickness Change (mm/yr) From5% CI, Change in Tau2, Statistical S gnificance, and REML StatistTable 4 Exp
(b) of Delta Mean Intima-Media Thickness Change (
95% CI, Change in Tau2, Statistical Significance, and R
Exp(b) SE
All-cause death
All trials (n  28) 0.14 0.68
Lipid lowering (n  12) 0.09 0.49
Antihypertensive (n  6) 0* 0*
Antidiabetics (n  3) 0* 0*
Antioxidant (n  2) NA NA
Primary prevention (n  19) 0.09 0.47
Secondary prevention (n  9) 18.12 266
Cerebrovascular events
All trials (n  33) 0.06 0.56
Lipid lowering (n  13) 0.01 0.01
Antihypertensive (n  7) 0* 0*
Antidiabetics (n  4) 0* 0*
Antioxidant (n  3) 0.97 0.09
Primary prevention (n  18) 0.02 0.32
Secondary prevention (n  14) 0.08 0.89
Coronary heart disease events
All trials (n  38) 45.25 188.9
Lipid lowering (n  18) 0.99 4.33
Antihypertensive (n  8) 1,000† 0*
Antidiabetics (n  4) 0* 0*
Antioxidant (n  3) 0* 0*
Primary prevention (n  23) 12.64 61.52
Secondary prevention (n  15) 24.3 176
Composite end point
All trials (n  32) 58.75 242
Lipid lowering (n  14) 2.35 10.56
Antihypertensive (n  7) 0.05 1.68
Antidiabetics (n  4) 0* 0*
Antioxidant (n  3) 0.95 0.04
Primary prevention (n  18) 69.46 359.05
Secondary prevention (n  14) 6.55 44
he number of trials included in the analysis is reported in parentheses. Symbols indicate that va
CI  confidence interval; NA  not available; REML  restricted maximum likelihood.or the composite outcome of CHD and CBV events (OR: (.90, 95% CI: 0.77 to 1.05, comparison p  0.19, heteroge-
eity p  0.05) (Online Appendix Fig. 9). All trends became
ignificant when the unsuccessful phase III trials using
holesteryl-ester transfer protein and a:cholesterol acyltrans-
erase inhibitors (CAPTIVATE, RADIANCE 1, and RA-
IANCE 2) were excluded (for CHD events, OR: 0.82, 95%
I: 0.69 to 0.96, comparison p  0.02, heterogeneity p 
.11; for CBV events, OR: 0.71, 95% CI: 0.51 to 1, compar-
son p  0.05, heterogeneity p  0.31; and for composite
vents, OR: 0.84, 95% CI: 0.72 to 0.99, comparison p 0.04,
eterogeneity p  0.19).
For more details about results by treatment category, refer
o Online Appendix Figures 6 through 9.
ublication bias. Macaskill’s modified test did not show
ny publication bias for each outcome (20).
iscussion
he main finding of the study is that carotid IMT changes
seline,or Ev ry Outcomeyr) From Baseline,
Statistics for Every Outcome
95% CI Change in Tau2 p au REML
0–1,000† 0.41 0.69 0
0–1,000† 0.44 0.67 0
0–0* 0.22 0.83 0
0–0* 0.6 0.65 0
NA NA NA NA
0–1,000† 0.47 0.65 0
0–0* 0.2 0.85 0
0–1,000† 0.32 0.75 0.01
0–0* 0.58 0.57 0
0–0* 1.61 0.17 0
0–0* 0.19 0.86 0
0.31–3.02 0.33 0.8 0
0–0* 0.28 0.78 0.04
0–0* 0.22 0.83 0
0.01–1,000† 0.91 0.37 0.1
0–1,000† 0 0.99 0
0–0* 0.36 0.73 0.33
0–0* 2.4 0.14 0
0–0* 0.8 0.57 0
0–1,000† 0.52 0.61 0.04
0–0* 0.44 0.67 0.18
.013–1,000† 0.99 0.33 0.12
0.01–1,000† 0.19 0.19 0.01
0–0* 0.10 0.93 0.18
0–0* 1.91 0.20 0
0.57–1.6 1.22 0.44 0
0–1,000† 0.82 0.42 0.76
0–0* 0.28 0.78 0.2
too small or †too large to be reported.
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Carotid IMT Changes and Cardiovascular Events December 7, 2010:2006–20he occurrence of major cardiovascular events induced by
everal drug treatments in different categories of subjects at
ntermediate to high cardiovascular risk (Figs. 2 and 3).
hus, IMT changes do not accurately predict the benefits of
herapies with proven favorable effects on cardiovascular risk
rofile. This observation held true when the relationship was
eparately assessed for different categories of active drugs, when
t was separately assessed in subjects with and without previous
ardiovascular disease, and when several common effect mod-
fiers were introduced in the analytic statistical modeling.
Although carotid IMT is currently included among organ
amage indicators in major cardiovascular guidelines (3,4),
nd increased IMT impacts on therapeutic strategy in
ndividual subjects (4), its use as a surrogate end point in
linical trials and interpretation of IMT changes as predic-
ors of clinical benefits remain debated, as also recently
eported by the U.S. Preventive Services Task Force
21,22). This is at variance with other organ damage
ndicators such as left ventricular hypertrophy and mi-
xp(b) of Delta Maximum Intima-Media Thickness Change (mm/yr)5% CI, Change in Ta 2, Statistical Signifi a ce, and REML StatistTable 5 Exp
(b) of Delta Max mum Intim -M di Thickness Chan
95% CI, Change in Tau2, Statistical Significance, and R
Exp(b) SE
All-cause death
All trials (n  21) 0.05 0.26
Lipid lowering (n  12) 0.02 0.11
Antihypertensive (n  3) 0 0
Antidiabetics (n  3) 0 0
Antioxidant (n  2) NA NA
Primary prevention (n  15) 0.03 0.16
Secondary prevention (n  6) 0 0
Cerebrovascular events
All trials (n  24) 0 0.05
Lipid lowering (n  11) 0 0.35
Antihypertensive (n  4) 0 0
Antidiabetics (n  3) 0 0
Antioxidant (n  4) 0.97 0.08
Primary prevention (n  13) 0 0
Secondary prevention (n  10) 0.87 10.57
Coronary heart disease events
All trials (n  29) 3.21 15
Lipid lowering (n  19) 0.14 0.61
Antihypertensive (n  5) 1,000† 0*
Antidiabetics (n  3) 0 0
Antioxidant (n  2) NA NA
Primary prevention (n  17) 26.9 153
Secondary prevention (n  12) 0.11 0.89
Composite end point
All trials (n  24) 4 17
Lipid lowering (n  12) 0.32 1.31
Antihypertensive (n  4) 0 0
Antidiabetics (n  3) 0 0
Antioxidant (n  3) 0.95 0.04
Primary prevention (n  13) 20.54 123.94
Secondary prevention (n  11) 0.74 4.86
he number of the trials included in the analysis is reported in parentheses. Symbols indicate tha
Abbreviations as in Table 4.roalbuminuria, for which association between regression lnd favorable cardiac and renal outcomes has been demon-
trated (23–25). However, the findings of the current study
o not detract from the value of carotid IMT as a risk
opulation marker or from the value of IMT assessment in
ndividual subjects (2,18), in particular for high IMT value
o be a proxy elsewhere in the body (26).
The lack of association between IMT changes and
linical outcomes is surprising, and the biologic explanations
or why carotid IMT and clinical outcomes are dissociated
an be only hypothesized and likely subject to considerable
ebate. As a first hypothesis, it is known that the process of
MT increase is a complex phenomenon, not only deter-
ined by atherosclerotic risk factors (27), and the role of
MT as a marker of atherosclerosis has been for this reason
ebated (2,28,29). Thus, it is conceivable that the multifac-
orial determinants of IMT may reduce the clinical strength
nd statistical significance of IMT changes as predictors of
ardiovascular outcomes when interventions on more direct
therosclerotic risk factors (e.g., LDL and blood pressure
Baseline,or Ev ry Outcomemm/yr) From Baseline,
Statistics for Every Outcome
95% CI Change in Tau2 p tau REML
0–1,000† 0.57 0.57 0
0–1,000† 0.67 0.52 0
0–0* 0.27 0.83 0
0–0* 0.73 0.60 0
NA NA NA NA
0–1,000† 0.65 0.53 0
0–0* 0.51 0.64 0
0–1,000† 0.52 0.61 0.13
0–0* 0.51 0.62 0
0–0* 0.93 0.45 0.35
0–0* 0.16 0.89 0
.32–2.97 0.33 0.80 0
0–0* 0.66 0.52 0.05
0–0* 0.01 0.99 0
0–1,000† 0.25 0.80 0.18
0–1,000† 0.45 0.66 0
0–0* 0.34 0.76 0.79
0–0* 2.55 0.24 0
NA NA NA NA
0–1,000† 0.58 0.57 0.11
0–1,000† 0.28 0.78 0.32
0–1,000† 0.32 0.75 0.16
0–1,000† 0.28 0.79 0
0–0* 1.97 0.19 0
0–0* 1.98 0.30 0.1
.57–1.6 1.23 0.44 0
0–0* 0.50 0.63 0.16
0–1,000† 0.05 0.96 0.21
is *too small or †too large to be reported.
2Fromics fge (
EML
0
0owering) are used. The second additional and relevant
h
a
t
t
m
(
t
a
s
a
I
(
m
r
c
r
I
b
h
t
s
i
t
S
o
PF
2017JACC Vol. 56, No. 24, 2010 Costanzo et al.
December 7, 2010:2006–20 Carotid IMT Changes and Cardiovascular Eventsypothesis that can explain our findings concerns the
ssumption that carotid wall injuries are representative of
he status of the whole arterial bed in the body, including
he coronary tree. Indeed, this has not been proven in the
ajority of subjects, by pathological post-mortem studies
30–34) and by clinical studies (35–38), indicating clearly
hat in the majority of patients, carotid lesions, including
therosclerotic plaques, are dissociated from coronary le-
ions. Finally, as atherosclerotic plaques grow longitudinally
long the carotid axis 2 times faster than they thicken,
MT might be a less sensitive measure of plaque evolution
39). In fact, it was demonstrated that carotid plaques are a
otential Effect Modifiers of Delta Mean and Maximum IMT Percenrom B seline With Change in Tau2 and Statistical Significance forTable 6 Po ential Effect Modifiers of Delta Mean a d MaximumFrom Baseline With Change in Tau2 and Statistical Sig
Delta Mea
Change in Tau2
All-cause death
Age 0.60
Women 0.40
BMI 0.28
Smokers 0.03
Diabetes mellitus 0.21
Hypertension 0.31
Total serum cholesterol 0.37
LDL baseline 0.38
Delta LDL 0.24
Systolic blood pressure baseline 0.16
Diastolic blood pressure baseline 0.49
Delta systolic blood pressure 0.49
Delta diastolic blood pressure 0.45
Mean IMT baseline 0.31
Maximum IMT baseline 0.33
Follow-up 0.29
Jadad quality score 0.55
Year 0.43
Cerebrovascular events
Age 0.18
Women 0.06
BMI 0.07
Smokers 0.76
Diabetes mellitus 0.22
Hypertension 0.12
Total serum cholesterol 0.04
LDL baseline 0.12
Delta LDL 0.17
Systolic blood pressure baseline 0.10
Diastolic blood pressure baseline 0.11
Delta systolic blood pressure 0.11
Delta diastolic blood pressure 0.55
Mean IMT baseline 0.16
Maximum IMT baseline 0.91
Follow-up 0.06
Jadad quality score 0.36
Year 0.33ore sensitive and representative measure of the atheroscle- hotic burden than IMT, with higher predictive value for
ardiovascular events (40,41). In addition, the lack of a clear
elation between change in IMT and LDL, and the fact that
MT association with coronary heart disease is influenced
y change in systolic blood pressure, might strengthen the
ypothesis that IMT is influenced by mechanisms such as
he shear stress and wall reactivity rather than pure athero-
clerotic processes. These observations may explain why IMT
s a very good population risk marker, whereas its value as a
herapeutic target in individual subjects may be limited.
tudy limitations. First, like all meta-analyses not based
n individual data, the findings should be considered only as
Changey OutcomePercentage Change
nce for Every Outcome
Delta Max IMT
p Value Change in Tau2 p Value
0.56 0.69 0.59
0.69 0.38 0.71
0.78 0.65 0.52
0.97 0.13 0.9
0.84 0.34 0.74
0.76 0.48 0.64
0.72 0.32 0.76
0.71 0.39 0.7
0.81 0.23 0.82
0.87 0 1
0.63 0.32 0.76
0.63 0.6 0.57
0.66 0.81 0.45
0.76 0.47 0.65
0.75 0.43 0.67
0.77 0.19 0.85
0.58 0.69 0.5
0.67 0.62 0.54
0.86 0.12 0.9
0.95 0.09 0.93
0.94 0.10 0.92
0.46 0.09 0.93
0.83 0.09 0.93
0.90 0.59 0.56
0.97 0.23 0.82
0.90 0.04 0.96
0.87 1.00 0.33
0.92 0.43 0.68
0.92 0.08 0.94
0.92 0.39 0.71
0.59 0.94 0.38
0.87 0.08 0.94
0.38 0.28 0.78
0.95 0.02 0.99
0.72 0.06 0.96
0.74 0.36 0.72
Continued on next pagetageEverIMT
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n IMTypothesis-generating and not as definitive evidence of a
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utcomes. Indeed, they should foster adequate intervention
rospective studies to assess whether IMT changes may be
onsidered a valid surrogate end point for monitoring of
ardiovascular risk profile in individual patients.
In addition, as it is inherent to meta-analyses, the uncertain
efinition and allocation of end points may differ among trials,
specially for soft end points. However, confirmation of our
ndings when only hard cardiovascular end points were
onsidered support our results and limits the potential
onfounding effect of this limitation (see Online Appendix
ig. 1 and Table 1).
Furthermore, several of the covariates included were trial
ontinuedTable 6 Continued
Delta Mea
Change in Tau2
Coronary heart disease events
Age 0.87
Women 1.01
BMI 1.11
Smokers 0.54
Diabetes mellitus 0.87
Hypertension 1.3
Total serum cholesterol 1.15
LDL baseline 1.00
Delta LDL 1.18
Systolic blood pressure baseline 1.4
Diastolic blood pressure baseline 1.36
Delta systolic blood pressure 0.53
Delta diastolic blood pressure 0.72
Mean IMT baseline 1.04
Maximum IMT baseline 0.78
Follow-up 1.09
Jadad quality score 0.69
Year 0.74
Composite outcome
Age 0.18
Women 0.06
BMI 0.07
Smokers 0.76
Diabetes mellitus 0.22
Hypertension 0.12
Total serum cholesterol 0.04
LDL baseline 0.10
Delta LDL 0.17
Systolic blood pressure baseline 0.10
Diastolic blood pressure baseline 0.04
Delta systolic blood pressure 0.11
Delta diastolic blood pressure 0.55
Mean IMT baseline 0.16
Maximum IMT baseline 0.08
Follow-up 0.06
Jadad quality score 0.36
Year 0.89
bbreviations as in Tables 1 and 2.evel, because of unavailability of access to individual study warticipant data. However, it has been reported that, when
he number of studies and of subjects in studies is not small,
eta-regression with aggregated data is reliable and mean-
ngful (42).
Although the selection of potential effect modifiers was
ade taking into account general characteristics, baseline
isk, IMT results, and quality of the trials, meta-
egression analysis could only be based on published
esults of the trials. Thus, complete information about
otential effect modifiers were not available for all trials
ncluded in the study. In addition, we selected trials that
easured carotid IMT and trials that reported clinical
vents; thus, large outcomes trials not reporting IMT
Delta Max IMT
p Value Change in Tau2 p Value
0.39 0.56 0.58
0.32 0.11 0.91
0.28 0.59 0.56
0.59 0.53 0.6
0.39 0.26 0.8
0.2 0.13 0.9
0.26 0.08 0.94
0.32 0.23 0.82
0.25 0.24 0.81
0.17 0.09 0.93
0.18 0.11 0.91
0.6 0.61 0.55
0.48 0.30 0.77
0.31 0.22 0.83
0.44 0.04 0.97
0.28 0.02 0.98
0.5 1.35 0.19
0.47 0.05 0.96
0.86 0.09 0.38
0.95 0.09 0.93
0.94 0.01 0.92
0.46 0.09 0.93
0.83 0.09 0.93
0.9 0.59 0.56
0.97 0.23 0.82
0.92 0.04 0.96
0.87 1.00 0.33
0.92 0.42 0.68
0.97 0.08 0.94
0.92 0.39 0.71
0.59 0.93 0.38
0.87 0.91 0.38
0.94 0.28 0.78
0.95 0.02 0.99
0.72 0.06 0.96
0.38 0.07 0.94n IMThere excluded. Therefore, the relationships between
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December 7, 2010:2006–20 Carotid IMT Changes and Cardiovascular Eventsome baseline measures (LDL, and so forth) are less
obust than those from larger outcomes trials.
Technical aspects concerning the reproducibility of serial
ithin-individual changes and lack of standardization of IMT
easurements may also play a role to explain the findings of
he present study in which trials using different methodological
pproaches were pooled. Indeed, carotid IMT measurements
re prone to generate variability in follow-up studies, mostly
onographer dependent. However, in controlled clinical trials,
easurement variability has been decreasing, owing to techni-
al improvements, standardization, and training (43). Further-
ore, in multicenter trials, images are handled and IMT
easurements recorded off line in a core ultrasound laboratory
hat limits, likely substantially, technical errors in measure-
ents. Yet, to take into account this potential limitation, we
erformed a sensitivity analysis with the year of trial publica-
ion as covariate that did not show a significant influence on
esults (Table 6). In addition, considering the potentially
uboptimal standardization of IMT measurement in small
tudies, we performed a sensitivity analysis excluding studies
hat did not measure IMT in a central core laboratory, and our
esults again did not significantly change.
onclusions
lthough IMT increase indicated an increased cardiovas-
ular risk, favorable changes induced by drug therapies do
ot consistently reflect improved clinical outcome.
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